Mesothelin-based CAR-T cells exhibit potent antitumor activity against ovarian cancer

• DOI: 10.1186/s12967-024-05174-y
• Publication Date: 2024-04-18T05:01:57Z
• Authors: Jing Guo; Xiaozhu Zeng; Yongjie Zhu; Dong Yang; Xudong Zhao
• Keywords: Mesothelin

Ovarian cancer (OC) is characterized by its rapid growth and spread which, accompanied a low 5-year survival rate, necessitates the development of improved treatments. In ovarian cancer, selective overexpression Mucin-16 (MUC16, CA125) in tumor cells highlights potential as promising target for developing anti-tumor therapies. However, effectiveness CAR-T cell therapy that targets MUC16 unknown.